Angelopoulos Theodoros P, Doupis John
Division of Diabetes, Iatriko Paleou Falirou Medical Center, Athens, Greece.
Adv Ther. 2014 Jun;31(6):579-91. doi: 10.1007/s12325-014-0127-7. Epub 2014 Jun 28.
Sodium-Glucose linked transporter 2 (SGLT2) inhibitors are a new family of antidiabetic pharmaceutical agents whose action is based on the inhibition of the glucose reabsorption pathway, resulting in glucosuria and a consequent reduction of the blood glucose levels, in patients with type 2 diabetes mellitus. Apart from lowering both fasting and postprandial blood glucose levels, without causing hypoglycemia, SGLT2 inhibitors have also shown a reduction in body weight and the systolic blood pressure. This review paper explores the renal involvement in glucose homeostasis providing also the latest safety and efficacy data for the European Medicines Agency and U.S. Food and Drug Administration approved SGLT2 inhibitors, looking, finally, into the future of this novel antidiabetic category of pharmaceutical agents.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一类新型抗糖尿病药物，其作用基于抑制葡萄糖重吸收途径，从而导致糖尿并进而降低2型糖尿病患者的血糖水平。除了降低空腹和餐后血糖水平且不引起低血糖外，SGLT2抑制剂还显示出体重减轻和收缩压降低。本文综述探讨了肾脏在葡萄糖稳态中的作用，还提供了欧洲药品管理局和美国食品药品监督管理局批准的SGLT2抑制剂的最新安全性和有效性数据，最后展望了这类新型抗糖尿病药物的未来。
